Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.60 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377692 | 1.00 | TRIM24 (0.60) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30770827 | 0.98 | ALDH1A1 (0.61) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1418736 | 0.98 | ALDH1A1 (0.61) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL27906847 | 0.85 | ADRB1 (0.55) | TRIM24TRIM33ALDH1A1MAPTHTR7 | |
| SCHEMBL13345896 | 0.84 | HTR7 (0.62) | ALDH1A1MAPTHTR7 | |
| SCHEMBL29442412 | 0.84 | ALDH1A1 (0.64) | ALDH1A1KDM4EGAAMAPTAGXT | |
| SCHEMBL31247769 | 0.84 | ALDH3A1 (0.55) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1444185 | 0.84 | ALDH1A1 (0.64) | ALDH1A1KDM4EGAAMAPTAGXT | |
| SCHEMBL1443605 | 0.84 | ALDH3A1 (0.55) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL21558444 | 0.81 | TRIM24 (0.61) | TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049164-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | claimed |
| CN-114025847-B | Compounds and compositions as modulators of TLR signaling | 神经孔疗法股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | US | disclosed |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3774736-B1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| CN-111592522-B | Arginine methylation transferase 5 small-molecule inhibitor and preparation method and application thereof | 郑州大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| CN-102695546-A | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2012-09-26 | — | — | CN | disclosed |
| EP-2475428-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-07-18 | — | — | EP | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
| WO-2009155362-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009038411-A2 | BETA-SECRETASE INHIBITING COMPOUNDS HAVING OXO-DIHYDRO-PYRAZOLE MOIETY | LG LIFE SCIENCES, LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298155-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING | TLR3, TLR6, TLR4 | TRIM24 1262/4885TRIM33 2157/4885ALDH1A1 4634/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | TRIM24 4272/4885TRIM33 3705/4885ALDH1A1 2282/4885 |
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | TRIM24 1671/4885TRIM33 2822/4885ALDH1A1 2195/4885 |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MYB, MYBBP1A, MYCBP | TRIM24 220/4885TRIM33 1410/4885ALDH1A1 4244/4885 |
| US-20220396583-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | TRIM24 1887/4885TRIM33 3127/4885ALDH1A1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.